MARKET

HMDCF

HMDCF

HUTCHMED (China) Limited
OTCPK
2.900
NaN%
Closed 09:30 07/30 EDT
OPEN
--
PREV CLOSE
2.900
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
2.900
52 WEEK LOW
2.900
MARKET CAP
2.53B
P/E (TTM)
5.54
1D
5D
1M
3M
1Y
5Y
1D
HUTCHMED Reports 2026 Interim Results
Barchart · 21h ago
HUTCHMED to Announce 2026 Half-Year Financial Results
Barchart · 06/30 03:30
HUTCHMED Highlights Pivotal Phase II Data for Fanregratinib in Intrahepatic Cholangiocarcinoma Presented at ESMO Gastrointestinal Cancers Congress 2026
Barchart · 06/24 19:00
HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress
Barchart · 06/11 19:00
HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting
Barchart · 05/21 19:00
HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Barchart · 04/29 05:00
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026
Barchart · 04/08 19:00
HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China
Barchart · 03/22 19:00
More
About HMDCF
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.

Webull offers HUTCHMED (China) Ltd stock information, including OTCPK: HMDCF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HMDCF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HMDCF stock methods without spending real money on the virtual paper trading platform.